


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A compound of Formula (I):



wherein:

R₁ is H or C₁₋₈ alkyl;

R₂ is C₁₋₄ alkyl, -CH₂-O-C₁₋₄ alkyl, C₁₋₄ haloalkyl or CH₂OH; and

R₃, R₄, R₅ and R₆ are each independently H, C₁₋₄ alkyl, amino, cyano, halogen, C₁₋₄ haloalkyl, nitro or OH; or

a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof;

provided that when R₂ is C₁₋₄ alkyl, -CH₂-O-C₁₋₄ alkyl, ~~[[and]]~~ or CH₂OH then R₃ and R₆ are not both hydrogen.

2. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₁ is H.

3. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₁ is C₁₋₈ alkyl.

4-8. (Canceled)

9. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₂ is C₁₋₄ alkyl.

10. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₂ is methyl.

11-13. (Canceled)

14. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₂ is C₁₋₄ haloalkyl.

15. (Canceled)

16. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₃ is H.

17. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₃ is C₁₋₄ alkyl.

18-20. (Canceled)

21. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₃ is halogen.

22-25. (Canceled)

26. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₃ is C₁₋₄ haloalkyl.

27-29. (Canceled)

30. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₄ is H.

31. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₄ is C₁₋₄ alkyl.

32-34. (Canceled)

35. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₄ is halogen.

36-39. (Canceled)

40. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₄ is C₁₋₄ haloalkyl.

41-43. (Canceled)

44. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₅ is H.

45. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₅ is C₁₋₄ alkyl.

46-48. (Canceled)

49. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₅ is halogen.

50-53. (Canceled)

54. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₅ is C₁₋₄ haloalkyl.

55-57. (Canceled)

58. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₆ is H.

59. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₆ is C₁₋₄ alkyl.

60-62. (Canceled)

63. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₆ is halogen.

64-67. (Canceled)

68. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein R₆ is C₁₋₄ haloalkyl.

69-71. (Canceled)

72. (Currently Amended) The compound of claim 1 selected from the group consisting of:

6,8-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

6-Chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

8-Chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and

8,9-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof.

73. (Currently Amended) The compound of claim 1 that is 9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof.

74. (Currently Amended) The compound of claim 1 selected from the group consisting of:

N-methyl-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; and
N-methyl-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof.

75. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein said compound is an R enantiomer.

76. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, wherein said compound is an S enantiomer.

77. (Currently Amended) A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof, and a pharmaceutically acceptable carrier.

78-80. (Canceled)

81. (Currently Amended) A method of treatment of a disorder selected from the group consisting of depression, atypical depression, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, Male erectile sexual dysfunction, psychoses, schizophrenia, epilepsy, drug and alcohol addiction, and obesity, comprising administering to an individual in need of such treatment a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof.

82. (Previously Presented) The method according to claim 81 wherein the disorder is obesity.

83. (Canceled)

84. (Currently Amended) The method according to claim 81 wherein the disorder sexual dysfunction is Male erectile dysfunction.

85-89. (Canceled)

90. (Previously Presented) The method according to claim 82 or 84 wherein said individual is a human.

91. (Currently Amended) A method of decreasing food intake of an individual comprising administering to said individual a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof.

92. (Canceled)

93. (Previously presented) The method according to claim 91 wherein said individual is a human.

94. (Currently Amended) A method of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate~~ thereof.

95. (Canceled)

96. (Previously presented) The method according to claim 94 wherein said individual is a human.

97. (Currently Amended) A method of controlling weight gain of an individual comprising administering to said individual suffering from weight control a therapeutically

effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate thereof~~.

98. (Canceled)

99. (Previously presented) The method according to claim 97 wherein said individual is a human.

100-103. (Canceled)

104. (Currently Amended) A method of producing a pharmaceutical composition comprising admixing at least one compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate thereof~~, and a pharmaceutically acceptable carrier.

105-123. (Canceled)

124. (Currently Amended) The compound according to claim 1, or a pharmaceutically acceptable salt, ~~hydrate or solvate thereof~~, wherein:

R₁ is H, methyl, ethyl, *n*-propyl, *iso*-propyl or *n*-butyl;

R₂ is methyl, ethyl, *iso*-propyl, *n*-butyl or -CF₃;

R₃ is H, -CH₃, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF₃, nitro or -OH;

R₄ is H, -CH₃, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF₃, nitro or -OH;

R₅ is H, -CH₃, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF₃, nitro or -OH; and

R₆ is H, -CH₃, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF₃, nitro or -OH.

125-131. (Canceled)